[
  {
    "ts": null,
    "headline": "Mastercard, Broadcom, Pfizer Among Two Dozen Companies To Announce Dividend Increases In December",
    "summary": "Itâll be a busy December for dividend growth investors, with 25 companies announcing their annual increases. Check out the companies with dividend increases.",
    "url": "https://finnhub.io/api/news?id=e8df62415007b1cb0c5667857cfef3bf3e946d231eb9845307afb01004b120e4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733087555,
      "headline": "Mastercard, Broadcom, Pfizer Among Two Dozen Companies To Announce Dividend Increases In December",
      "id": 131733371,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/458117345/image_458117345.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Itâll be a busy December for dividend growth investors, with 25 companies announcing their annual increases. Check out the companies with dividend increases.",
      "url": "https://finnhub.io/api/news?id=e8df62415007b1cb0c5667857cfef3bf3e946d231eb9845307afb01004b120e4"
    }
  },
  {
    "ts": null,
    "headline": "BeiGene: Nearing Profitability On TEVIMBRA Approval In The EU And US",
    "summary": "BeiGene's TEVIMBRA was just approved by the European Commission. Find out what makes BGNE a compelling aggressive growth stock with substantial upside potential.",
    "url": "https://finnhub.io/api/news?id=09e6acc6a35c6dd9f15f1a9a82f98a7ca1fc8fada3c7cca44d3471e712f49e9b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733043600,
      "headline": "BeiGene: Nearing Profitability On TEVIMBRA Approval In The EU And US",
      "id": 131730287,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1806224504/image_1806224504.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "BeiGene's TEVIMBRA was just approved by the European Commission. Find out what makes BGNE a compelling aggressive growth stock with substantial upside potential.",
      "url": "https://finnhub.io/api/news?id=09e6acc6a35c6dd9f15f1a9a82f98a7ca1fc8fada3c7cca44d3471e712f49e9b"
    }
  },
  {
    "ts": null,
    "headline": "Instil Bio's Strategic Shift To SYN-2510: A Speculative 'Buy' Opportunity",
    "summary": "Instil Bio is a clinical-stage biotech focusing on personalized immunotherapy. Check out my recommendation for TIL stock.",
    "url": "https://finnhub.io/api/news?id=24ba388d90ace7e455223780077c37f5075e9dca177dd9bce4121a5e9550b64e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733029226,
      "headline": "Instil Bio's Strategic Shift To SYN-2510: A Speculative 'Buy' Opportunity",
      "id": 131729228,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1137002286/image_1137002286.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Instil Bio is a clinical-stage biotech focusing on personalized immunotherapy. Check out my recommendation for TIL stock.",
      "url": "https://finnhub.io/api/news?id=24ba388d90ace7e455223780077c37f5075e9dca177dd9bce4121a5e9550b64e"
    }
  }
]